

LITERATURA

1. Abubara K, Ye M, McCulloch Ch et al. Clinical onset of atopic eczema: Results from 2 nationally representative British birth cohorts followed through midlife. *J Allergy Clin Immunol*. 2019;144:710–19.
2. Adalsteinsson JA, Kaushok S, Muzumdar S et al. An update on the microbiology, imunology and genetics of seborrheic dermatitis. *Exp Dermatol*. 2020;29:481–9.
3. Armstrong A, Hahn-Pedersen J, Bartlett C, et al. Economic burden of chronic hand eczema: a review. *Am J Clin Dermatol*. 2022;23(3):287–300.
4. Bangert Ch, Friedl J, Stary G, Stingl G. Immunopathologic features of allergic contact dermatitis. *J Invest Dermatol*. 2003;121:1409–18.
5. Barbarot S, Stalder JF. Therapeutic patient education in atopic eczema. *Br J Dermatol*. 2014;170 (Suppl. 1):44–8.
6. Barbarot S, Auziere S, Gadkari A et al. Epidemiology of atopic dermatitis in adults: Results of international survey. *Allergy*. 2018;73:1284–93.
7. Bělohlávková, S. Potravinová alergie u atopické dermatitidy. *Dermatol Praxi*. 2020;14 (4):197–201.
8. Benáková N. Optimální využití lokálních kortikoidů a imunomodulátorů v dlouhodobé léčbě atopické dermatitidy. *Farmakoterapie*. 2011;7(5):595–600.
9. Benáková N. Terapeutická edukace v dermatologii. *Čs Derm*. 2015;90(1):4–12.
10. Benáková N. Jak je to s prevalencí atopické dermatitidy v České republice? *Čs Derm*. 2023;98(1):15–24.
11. Bissonnette R, Agner T, Molin S et al. Hand Eczema. Part 1: epidemiology, pathogenesis, diagnosis and work-up. *J Am Acad Dermatol*. 2024 Oct 5:S0190-9622(24)02952-9.
12. Bissonnette R, Agner T, Taylor JS et al. Hand Eczema. Part 2: Prevention, management, and treatment. *J Am Acad Dermatol*. 2024 Oct 5:S0190-9622(24)02953-0.
13. Braun-Falco O, Plewig G, Wolff HH, Burgdorf WHC. *Dermatology*. 2nd ed. Springer Verlag; 2000. p. 457–517.
14. Criado PC, Miot HA, Bueno-Filho R at al. Update on the pathogenesis of atopic dermatitis. *Anais Brasileiros de dermatologia*. 2024;1–21.
15. Čapková Š. Současné možnosti léčby atopické dermatitidy v dětském věku a poučení rodičů. Referátový výběr z dermatovenerologie. 2004;46(1):5–12.
16. Čapková Š. Rizika lokální léčby v kojeneckém a dětském věku. Referátový výběr. 2007;III:13–18.
17. Dall'Oglio F, Nasca MR, Gerbino C et al. An overview of the diagnosis et management of seborrheic dermatitis. *Clin Cosmet Invest Dermatol*. 2022;15:1537–48.

18. Dastychová E. Kontaktní a iritační dermatitida. *Postgraduální medicína*. 2004;6(3):312–17.
19. Dastychová E. Kožní choroby z povolání. Referátový výběr. 2009;3:22–36.
20. Diepgen TL, Andersen KE, Brandao FM, et al. Hand eczema classification: a cross-sectional, multicentre study of the aetiology and morphology of hand eczema. *Br J Dermatol*. 2009;160(2):353–8.
21. Drucker AM, Eyrich K, de Bruin-Weller MS et al. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. *Br J. Dermatol*. 2018;178(3):768–75.
22. Dubin C, Del Duca E, Guttman-Yassky E. Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges. *Ther Clin Risk Manag*. 2020;16:1319–32.
23. Egeberg A, Thyssen JP. Topical corticosteroid in the era of new topical therapies: balancing efficacy and safety for long-term use. *JEADV*. 2024;38:126–7.
24. Ettler K. Fotodermatózy a fotoprotekce. In: Benáková N et al. *Moderní farmakoterapie v dermatologii*, 2. vyd. Praha: Maxdorf; 2023. p. 94–106.
25. Fadrhonicová A. Farmakoterapie kožních nemocí. Praha: Grada Avicenum; 1999;70–80, 326–9.
26. Finch J, Munhutu MN, Whitaker-Worth D. Atopic dermatitis and nutrition. *Clin Dermatol*. 2010;28:605–14.
27. Fluhr JW, Moore DJ, Lane ME et al. Epidermal barrier function in dry, flaky and sensitive skin: a narrative review. *JEADV*. 2024;38:812–20.
28. Gamblicher T, Tomi NS, Huyn J et al. Topical tacrolimus neither prevents nor abolishes ultraviolet -induced erythema. *JAAD*. 2006;55(5):882–5.
29. Gibson J, et al. An assesment of relationship between vasoconstriction assay findings, clinical efficiacy and skin thinning effects of undiluted and diluted corticosteroid preparations. *Br J Dermatol*. 1984;Suppl 27:204–12.
30. Goujon C, Berard F, Dahel K et al. Methotrexate for the treatment of adult atopic dermatitis. *Eur J Dermatol*. 2006;16:155–8.
31. Grada A, Bunick CG. Demystifying hand eczema. *J Invest Dermatol*. 2023;143(8):1338–9.
32. Gupta AK, Blum R. Seborrhoeic dermatitis. *JEADV*. 2004;18:13–26.
33. Hašek J. Lokální kortikosteroidy v magistraliter receptuře. *Prakt lékařén*. 2019;15(2):111–16.
34. Hašek J. Basiscreme DAC-nový krémový základ pro magistraliter přípravu. *Prakt lékařén*. 2014;10(6):221–5.
35. Hauk PJ, Hamid QA, Chrousos GP, et al. Induction of corticosteroid insensitivity in human peripheral blood mononuclear cells by microbial superantigens. *J Allergy Clin Immunol*. 2000;105:782–7.
36. Herman E, Praško J, Seifertová E. *Konsiliární psychiatrie*. Praha: Medical Tribune; 2007.
37. Hoefakker S, Caubo M, Erve EH et al. In vivo cytokine profiles in allergic and irritant contact dermatitis. *Contact Dermatitis*. 1995;33(4):258–66.
38. Ho JSS, Molin S. A review of existing and new treatments for the management of hand eczema. *J Cutan Med Surg*. 2023;27:493–503.

39. Humeau M. et al. Cytokine-mediated crosstalk between keratinocytes and T cells in atopic dermatitis. *Front Immunol.* 2022;13:801597.
40. Chandra SHV et al. Cutaneous Malassezia: Commensal, Pathogen, or Protector? *Front Cel Infect Microbiol.* 2021;10:614446.
41. Loffler H, Effendy I, Happle R. Die irritative Kontaktdermatitis. *Hautarzt.* 2000;51:203–18.
42. Jedličková A. Antimikrobiální terapie v každodenní praxi. 2nd ed. Praha: Maxdorf; 2004.
43. Johansen JD, Bonefeld CM, Schwensen JFB, et al. Novel insights into contact dermatitis. *J Allergy Clin Immunol.* 2022;149(4):1162–71.
44. Johansen JD, Hald M, Andersen BL, et al. Classification of hand eczema: clinical and aetiological types. Based on the guideline of the Danish contact dermatitis group. *Contact Dermatitis.* 2011;65(1):13–21.
45. Kilgore Ch. Atopic Dermatitis in Older Adults: Common, Unique, and Challenging to Manage. Medscape July 11, 2024, www.medscape.com.
46. Koo JYM, Chai SL. Psychocutaneous medicine. New York: Marcel Dekker; 2003. p. 427–51.
47. Lan CC, Fang AH, Wu PH, WU CS. Tacrolimus abrogates TGF β 1-induced type i collagen production in normal human fibroblast through suppressing p38MAPK signalling pathway: implications on treatment of chronic atopic dermatitis. *JEADV.* 2014;28(2):204–15.
48. Lazar M, Zhang AD, Vashi NA. Topical treatments in atopic dermatitis.:an expansive review. *J Clin Med.* 2024;13:285.
49. Lee HY, Stieger M, Yawalkar N, Kakeda M: Cytokines and chemokines in irritant contact dermatitis. *Mediators Inflamm.* 2013;2013:916497.
50. Li X, Zhao M, Li Y et al. A two-sample bidirectional Mendelian randomization study revealed atopic dermatitis is associated with an increased risk of migraine. *JEADV.* 2024;38(8):e660–662.
51. Litchman G, Nair PA, Atwater AR, Bhutta BS. Contact dermatitis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024.
52. Luger T, editor. Redefining treatment options in chronic hand eczema. *JEADV.* 2010;24(Suppl 3):1–20.
53. Marks R. Eczema. Martin Dunitz UK; 1992.
54. Martin SF. Contact dermatitis: from pathomechanism to immunotoxicology. *Exp Dermatol.* 2012;21:382–9.
55. McFadden JP, Dearman RJ, White JML et al. The hapten-atopy hypothesis. *Clin Exp Allerg.* 2011;41:327–37.
56. Mornstein V. Alternativní medicína. Postgraduální medicína. 2005;3:277–81.
57. Müller S, Maintz L, Bieber T. Treatment of atopic dermatitis: recently approved drugs and advanced clinical development programs. *Allergy.* 2024;79:1501–15.
58. Nakajima S, Igyártó B, Honda T et al. Langerhans cells are critical in epicutaneous sensitisation with protein antigen via TSLP receptor signaling. *J Allergy Clin Immunol.* 2012;129(4):1048–55.
59. Numata T, Harada K, Nakae S. Roles of mastocytes in cutaneous diseases. *Front. Immunol.* 2022;13:923495.
60. Niedner R. Therapie mit systemischen Glukokortikoiden. *Hautarzt.* 2001;52:1062–72.

61. Novotný F et al. Ekzémová onemocnění v praxi. Praha: Grada Avicenum; 1993.
62. Obrtel J. Zjišťování zevních příčin ekzému. Praha: SZN; 1954.
63. Pánková R. Psychodermatologie v ambulantní praxi. Zdravotnické noviny. 2005;54(17):14–6.
64. Pánková R. Psychofarmaka v dermatologii. Čes-slov Derm. 2014;89(3):95–106.
65. Pesque D, Aerts O, Bizjak M et al. Differential diagnosis of contact dermatitis. A practical-approach review by the EADV Task Force on contact dermatitis. JEADV. 2024;38:1604–22.
66. Polášková S. Léčba atopického ekzému. Practicus. 2006;1:404–6.
67. Polášková S. Emoliencia- základní bariérová externa. Dermatol praxi. 2013;3:127–9.
68. Poloučková A et al. Možnosti celkové léčby závažných forem atopického ekzému u dětí pohledem imunologa-alergologa. Referátový výběr. 2008;1:26–36.
69. Quaade AS, Simonsen AB, Halling AS et al. Prevalence, incidence and severity of hand eczema in the general population. Contact Dermatitis. 2021;84(6):361–74.
70. Ring J, Przbilla B, Ruzicka T. Handbook of atopic dermatitis. 2nd ed. Berlin-Heidelberg: Springer; 2006.
71. Rönsch H, Schiffers F, Ofenloch R et al. Chronic hand eczema in Europe: patient experiences and perspectives in qualitative interviews. JEADV. 2023;37(7):1396–45.
72. Rook A, Wilkinson DS, Ebling FJG, et al. Textbook of dermatology. 7th ed. London: Blackwell; 2004. p. 17.1–17.54.
73. Sans-de San Nicolas L, Czarnowicki T, Akdis M. et al. CLA+ memory cells in atopic dermatitis. Allergy. 2024;79/1:15–25.
74. Semrádová V. Léčba zevními kortikosteroidy: věda i umění. Čs Derm. 1997;72(1):27–32.
75. Sklenář Z. Magistraliter preskripce v dermatologii. Praha: Galén; 2009 a 2021.
76. Spergel JM. From atopic dermatitis to asthma: the atopic march. Ann Allergy Asthma Immunol. 2010;105:99–106.
77. Štork J, Arenberger P, Pizinger K. Dermatovenerologie. Praha: Galén; 2008. p. 149–75.
78. Thestrup-Pedersen K. Treatment principles of atopic dermatitis. JEADV. 2002;16:1–9.
79. Thyssen JP, Silverberg JI, Guttman-Yassky E. Chronic hand eczema understanding has ramifications on clinical management. JEADV. 2020;34(8):e429–e430.
80. Thyssen, JP et al. Guidelines for diagnosis, prevention and treatment of hand eczema. Contact Dermatitis. 2022;86:357–78.
81. Urbanček S, Dastychová E, Buchvald D, Vocilková A. Kontaktné alergény v pracovnom a životnom prostredí. Banská Bystrica: Polygrafia Gutenberg; 2005.
82. Viktorinová M. Kortikosteroidy pro lokální léčbu u kožních chorob. Remedia. 2003;13(4):266–82.
83. Vocilková A. Kontaktní dermatitida - teorie, spíše však praxe. Referátový výběr. 2010;4:48–50.
84. Vocilková A. Epikutánní testy. Referátový výběr. 2011;7:44–9.

85. Wang X. et al. Interleukin 18 and IL-18 BP in inflammatory dermatological diseases. *Front Immunol.* 2023;14:955369.
86. Wollenberg A, et al. JEADV. European guideline on atopic eczema: part II- non systemic treatments 2022; 36(11):1904–22 and part I- -systemic therapy 2022; 36(9): 1409–31.
87. Záhorský J. Zevní dermatologická terapie a kosmetika. Praha: Grada. 2006.
88. Záruba F, Vosmík F. Diferenciální diagnostika kožních chorob. Praha: Avicenum; 1988.
89. Zhang XE, Zheng P, Ye SZ et al. Microbiome: role in inflammatory skin diseases. *J Inflamm Res.* 2024;17:1057–82.
90. Zhou S, Li Q, Wu H et al. The pathogenic role of innate lymphoid cells in autoimmune- related and inflammatory skin diseases. *Cellular Molecular Immunology*, 2020; 17(4):335–46.